Workflow
Research Solutions(RSSS) - 2024 Q3 - Quarterly Results
RSSSResearch Solutions(RSSS)2024-05-09 20:11

Revenue Growth - Total revenue increased by 17% to 12.1million,drivenbyplatformrevenuegrowth[4][5]−Platformrevenuegrew7612.1 million, driven by platform revenue growth[4][5] - Platform revenue grew 76% to 4.0 million, with Annual Recurring Revenue (ARR) up 82% to 16.6million[5][6]−TotalrevenueforQ12024was16.6 million[5][6] - Total revenue for Q1 2024 was 12,115,672, a 17.1% increase from 10,342,426inQ12023[21]ProfitabilityMetrics−Grossprofitincreasedby3610,342,426 in Q1 2023[21] Profitability Metrics - Gross profit increased by 36%, with total gross margin improving 630 basis points to 45.2%[5][8] - Adjusted EBITDA reached a company record of 961,000, a 71.8% increase from the prior-year quarter[5][9] - Adjusted EBITDA for Q1 2024 was 960,740,a71.8960,740, a 71.8% increase from 559,382 in Q1 2023[15] - Gross profit for Q1 2024 was 5,481,932,a36.15,481,932, a 36.1% increase from 4,027,273 in Q1 2023[21] Customer and Transaction Metrics - Transaction revenue was 8.2million,with1,426activecustomers,aslightincreasefrom1,417intheprior−yearquarter[7]−Activecustomeraccountsaredefinedasthesumoftotalcustomerspermonthdividedbythenumberofmonthsintheperiod,withcustomershavingatleastonetransactionpermonth[12]−B2BARRincreasedby27.98.2 million, with 1,426 active customers, a slight increase from 1,417 in the prior-year quarter[7] - Active customer accounts are defined as the sum of total customers per month divided by the number of months in the period, with customers having at least one transaction per month[12] - B2B ARR increased by 27.9% to 11.65 million, while B2C ARR reached 4.9million[11]−AnnualRecurringRevenue(ARR)iscalculatedastheannualizedvalueofmonthlysubscriptions,multipliedbytwelveforB2CARR[13]OperatingExpensesandNetIncome−Totaloperatingexpensesincreasedby38.54.9 million[11] - Annual Recurring Revenue (ARR) is calculated as the annualized value of monthly subscriptions, multiplied by twelve for B2C ARR[13] Operating Expenses and Net Income - Total operating expenses increased by 38.5% to 5.4 million, primarily due to acquisitions[8] - Net income was 76,000,comparedto76,000, compared to 237,000 in the prior-year quarter[9] - Net income for Q1 2024 was 76,301,a67.876,301, a 67.8% decrease from 236,842 in Q1 2023[15] - Net income (loss) for the nine months ended March 31, 2024, was (965,370),comparedto(965,370), compared to 195,877 in the same period in 2023[23] Cash Flow and Financial Position - Quarterly cash flow from operations exceeded 2million,acompanyquarterlyrecord[5]−CashandcashequivalentsasofMarch31,2024,were2 million, a company quarterly record[5] - Cash and cash equivalents as of March 31, 2024, were 4,221,424, a decrease from 13,545,333asofJune30,2023[19]−AccountsreceivableasofMarch31,2024,were13,545,333 as of June 30, 2023[19] - Accounts receivable as of March 31, 2024, were 7,323,379, an increase from 6,153,063asofJune30,2023[19]−TotalassetsasofMarch31,2024,were6,153,063 as of June 30, 2023[19] - Total assets as of March 31, 2024, were 40,803,199, an increase from 21,834,727asofJune30,2023[19]−TotalliabilitiesasofMarch31,2024,were21,834,727 as of June 30, 2023[19] - Total liabilities as of March 31, 2024, were 26,674,940, an increase from 14,504,240asofJune30,2023[19]−NetcashprovidedbyoperatingactivitiesfortheninemonthsendedMarch31,2024,was14,504,240 as of June 30, 2023[19] - Net cash provided by operating activities for the nine months ended March 31, 2024, was 1,589,791, down from 1,872,356inthesameperiodin2023[23]−NetcashusedininvestingactivitiesfortheninemonthsendedMarch31,2024,was1,872,356 in the same period in 2023[23] - Net cash used in investing activities for the nine months ended March 31, 2024, was (10,081,507), primarily due to acquisitions of Resolute and Scite[23] - Net cash used in financing activities for the nine months ended March 31, 2024, was (836,984),includingcommonstockrepurchasesof(836,984), including common stock repurchases of (522,024)[23] - Cash and cash equivalents decreased by 9,323,909to9,323,909 to 4,221,424 at the end of March 31, 2024, from 13,545,333atthebeginningoftheperiod[23]Depreciation,Amortization,andOtherExpenses−Depreciationandamortizationexpensesincreasedto13,545,333 at the beginning of the period[23] Depreciation, Amortization, and Other Expenses - Depreciation and amortization expenses increased to 525,267 for the nine months ended March 31, 2024, from 30,486inthesameperiodin2023[23]−Fairvalueofvestedrestrictedcommonstockincreasedto30,486 in the same period in 2023[23] - Fair value of vested restricted common stock increased to 1,603,820 for the nine months ended March 31, 2024, from 925,550inthesameperiodin2023[23]−Accountsreceivabledecreasedby925,550 in the same period in 2023[23] - Accounts receivable decreased by 739,883 for the nine months ended March 31, 2024, compared to a decrease of 1,545,695inthesameperiodin2023[23]−Deferredrevenueincreasedby1,545,695 in the same period in 2023[23] - Deferred revenue increased by 768,347 for the nine months ended March 31, 2024, compared to an increase of 986,044inthesameperiodin2023[23]−Cashpaidforincometaxesincreasedto986,044 in the same period in 2023[23] - Cash paid for income taxes increased to 82,049 for the nine months ended March 31, 2024, from $5,543 in the same period in 2023[23] Product Launches - The company launched two new product offerings: Technology Landscape and Clinical Trial Landscape[3]